Merck said the FDA has accepted its biologics-license application for an experimental immunotherapy to treat grass pollen allergy. Instead of providing temporary relief of allergy symptoms, the treatment targets the causes of the allergic reaction and reduces symptoms such as itching and sneezing gradually. Merck expects the agency to release its decision early next year.
FDA accepts Merck's grass pollen allergy treatment for review
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||